KING OF PRUSSIA, Pa.,
Sept. 30, 2014 /PRNewswire/
-- CSL Behring announced that it is set to commence operations
in its newly expanded facility now that the U.S. Food & Drug
Administration (FDA) has granted approval. The expansion
significantly increases plasma processing and albumin production
capacity in the Kankakee, Ill.
facility.
The new facility will use the same state-of-the-art technology
as CSL Behring's long-standing manufacturing center of excellence
in Bern, Switzerland. This is an
important step towards a common fractionation process throughout
CSL Behring's global manufacturing network. The expansion is
necessary due to the growing worldwide demand for CSL Behring's
immunoglobulins and albumin.
CSL Behring's Executive Vice President Global Operations and
Planning, Mary Sontrop, said the
expansion in Kankakee is part of
CSL Behring's multi-site expansion plan, which includes the
expansion of its manufacturing facilities in Broadmeadows,
Australia; Bern, Switzerland; and Marburg, Germany.
"CSL Behring is committed to serving patients with rare diseases
in all corners of the world," Sontrop said. "In today's competitive
market, we continually explore the latest technology that's
available, and evaluate how it can make our operations and physical
plant more efficient to meet patients' growing needs. Increasing
Kankakee's ability to fractionate
plasma and produce albumin and intermediate paste is an important
step for our global operations."
Sontrop explained that the intermediate paste produced in
Kankakee is sent to CSL Behring's
other manufacturing facilities where it is used to make therapies
for the treatment of immune deficiencies, bleeding and other
medical disorders. Albumin is a plasma expander that quickly makes
up for blood loss in accident victims, and that is also used to
treat burn patients.
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic diseases in the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
http://www.cslbehring.com/.
Contact:
Chris Florentz, CSL Behring
610-878-4316
Christopher.Florentz@cslbehring.com
Logo- http://photos.prnewswire.com/prnh/20100914/PH63692LOGO
SOURCE CSL Behring